Skip to main content

Lung Cancer (NSCLC) Licensing Deal Benchmarks

Median Upfront
$258M
Range: $144M - $401M
Total Deal Value
$1.6B
Range: $1.1B - $2.2B
Royalty Rate
11.8% - 19.3%
Tiered up to 23.3%
Dev Milestones
$345M
Range: $230M - $452M
Model Your Deal

Market Analysis

Non-small cell lung cancer remains the single largest indication by licensing deal volume in oncology. Phase 2 NSCLC deals carry a median total deal value of $1.6B, with upfronts averaging $258M. The enormous addressable market -- over 230,000 new US cases annually -- sustains strong licensee demand despite an increasingly crowded competitive landscape.

Deal structures in NSCLC reflect the high commercial ceiling and well-defined regulatory pathways. Development milestones average $345M, with regulatory milestones of $552M and commercial milestones reaching $483M. The 16/84 upfront/milestone split balances early-stage risk with blockbuster upside.

Royalty rates for NSCLC licensing deals range from 11.8% to 19.3%, with tiered escalation to 23.3%. Assets targeting specific driver mutations (KRAS G12C, EGFR exon 20, MET amplification) command premium terms, while IO-combination approaches face increasing competitive pressure.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for NSCLC licensing agreements?
Phase 2 NSCLC deals average $258M upfront with $1.6B total deal value. Valuations are driven by the enormous addressable market, clear regulatory pathways, and line-of-therapy positioning.
How does biomarker selection affect NSCLC deal terms?
Biomarker-selected NSCLC assets (targeting specific mutations) command 10-20% premium in deal terms over broad/unselected approaches. The clearer development path, smaller trial sizes, and higher response rates translate to favorable risk-adjusted economics for licensees.
What competitive factors influence NSCLC deal valuations?
Key factors include line-of-therapy positioning (1L vs. 2L+), mechanism differentiation from pembrolizumab and other IO agents, combinability with existing standards, and strength of biomarker-selection strategy. Assets targeting underserved molecular subsets command the highest premiums.
How do NSCLC royalty rates compare across modalities?
Base royalty rates of 11.8%-19.3% are consistent across modalities for NSCLC, though biologics and cell therapies may command slightly higher rates. The large addressable market supports aggressive commercial milestone structures.

Related Benchmarks

Breast Cancer Deal Benchmarks

View

Small Molecule Deals

View

ADC Deal Benchmarks

View

Oncology Deal Overview 2026

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating